| Run-in Week −2 | Intervention A & B | |||
---|---|---|---|---|---|
Baseline | Mid point | End point | |||
 | Week 0 & 11 | Week 3 & 14 | Week 6 & 17 | ||
Serum uremic toxins | Indoxyl sulphate (free and total) | X | X | X | X |
P-cresyl sulphate (free and total) | X | X | X | X | |
Cardiovascular risk | Oxidative stress | Â | X | Â | X |
Inflammation | Â | X | Â | X | |
 | Endotoxemia (lipopolysaccharide) |  | X |  | X |
Kidney damage | 24 hr albuminuria and protienuria | Â | X | Â | X |
Kidney injury molecule-1 | Â | X | Â | X | |
 | Estimated glomerular filtration rate | X | X |  | X |
Dietary | Diet history interview | X | Â | Â | X |
24 hr recall | Â | X | X | Â | |
 | 24 hr urinary urea nitrogen |  | X |  | X |
Quality of life | Short Form-36 | Â | Â | Â | X |
Gastrointestinal symptoms | Gastrointestinal symptom rating scale | X | Â | X | X |
Gut microbiota | Fecal sample (optional) | Â | X | Â | X |
Compliance | Pill count | Â | Â | X | X |
Dose escalation | Â | Â | X | Â |